Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Erythropoietin Stimulating Agents Market size was valued at USD 18.08 billion in 2024 and is likely to cross USD 63.91 billion by 2037, registering more than 10.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of erythropoietin stimulating agents is estimated at USD 19.65 billion.
Erythropoietin Stimulating Agents Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Incidences of Chronic Kidney Disease and Cancer to Expand the Market: Chronic Kidney Disease is more common in older people aged 65 and above, with 38% prevalence, as compared with people aged 18-44 years (7%) and 45-64 years (13%) in the United States as per the CDC. The rising cases of this disorder along with other renal disorders that have a direct impact on the blood cells results in an increased demand for erythropoietin stimulating agents. Moreover, the growing incidences of various types of cancers, especially blood cancers, is another factor resulting in a high demand for blood cells in the body. These factors are anticipated to lead to the erythropoietin stimulating agents market growth over the forecast period. According to the statistics presented by the Leukemia & Lymphoma Society, it was suggested that a total of 176,200 people living in the United States were expected to be diagnosed with leukemia, lymphoma or myeloma in 2019.
- Increase in Production of Biosimilar Drugs to Boost the Market Growth: Numerous pharmaceutical manufacturers are taking initiatives to develop and produce erythropoietin stimulating agents (ESAs) after the expiration of Amgen’s patent for Epogen. The growing commercialization of these drugs further results in reduction of their prices. This is anticipated to become another growth factor for the erythropoietin stimulating agents market in the upcoming years.
Challenges
- Side Effects Associated with EPAs to Restrict the Market Growth: Erythropoietin stimulating agents have been known to exhibit certain side effects in patients taking them as drugs. These might include, fever, swelling, high blood pressure, nausea, dizziness and pain at the injection site. This is estimated to restrict the market growth during the forecast period.
Erythropoietin Stimulating Agents Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
10.2% |
|
Base Year Market Size (2023) |
USD 16.41 billion |
|
Forecast Year Market Size (2036) |
USD 58.01 billion |
|
Regional Scope |
|
Erythropoietin Stimulating Agents Segmentation
The erythropoietin stimulating agents market is segmented by agent, by application and by region, out of which, the application segment is further divided into cancer, neural disorders, kidney disorders, anemia and others.
According to Centers for Disease Control and Prevention (CDC), 15% of total number of adults in the United States, i.e., around 37 million people were estimated to have chronic kidney disease in 2019.
On the basis of this, the kidney disorders segment is anticipated to hold the largest share in the market as a result of erythropoietin stimulating agents being used for the treatment of anemia among patients with chronic kidney disease. Additionally, the cancer segment is anticipated to hold a significant share in the erythropoietin stimulating agents market on account of growing use of erythropoietin for improving anemia in cancer patients. Data presented by the World Bank indicated that the prevalence of anemia among women between 15 and 49 years, i.e., of the reproductive age, is 32.8% in the world. Cancer-associated anemia interferes with cancer therapies, including chemotherapy, which increases the demand for these agents.
Our in-depth analysis of the global market includes the following segments:
|
By Agent |
|
|
By Application |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportErythropoietin Stimulating Agents Industry - Regional Synopsis
On the basis of regional analysis, the erythropoietin stimulating agents market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific industry is poised to hold largest revenue share by 2037, driven by growing developments and innovations in the field of medicine in the region. Moreover, the rising purchasing power of people and growth in medical tourism are anticipated to lead to the market growth as well. Erythropoietin stimulating agents have displayed high effectiveness when used in the treatment of various disorders such as neural disorders, cancer, chronic kidney disease (CKD) and anemia, among several others. The market for erythropoietin stimulating agents in North America is estimated to hold the largest share in the erythropoietin stimulating agents market on account of high occurrence of various disorders that eventually cause anemia in the region.
Companies Dominating the Erythropoietin Stimulating Agents Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson Services, Inc.
- Thermo Fisher Scientific
- Fuji Pharma
- Cigna
- Sandoz International GmbH
- Biocon
- 3SBio Group
In the News
Author Credits: Radhika Pawar
- Report ID: 2255
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
